Least : Actualité Least en direct - P3 | Bourse Reflex
Accueil > Tags > Least

  • Toutes les actualités en rapport avec « Least »

30/11 18:00 Least - BOGART GROUP to carry out capital increase by private placement

10/08 18:00 Least - New EUR 18 million financing aimed at accelerating the development in connected health, particularly in the USA

30/06 07:00 Least - NATUREX unveils its strategic plan " BRIGHT2020 "

04/05 19:15 Least - REVENUE FOR THE FIRST NINE MONTHS OF 2014/15

25/02 19:00 Least - Quantum Genomics reports total capital increase after stabilization period: EUR 12.9 million

16/02 20:50 Least - Artprice: the Art Market heading towards billion-dollar auction prices.

02/02 18:30 Least - Genticel licenses Vaxiclase platform to Serum Institute of India for use in pertussis vaccines

27/01 19:20 Least - Business Update - Fourth Quarter 2014

21/01 18:00 Least - Sustained growth in 2014/15 nine-month revenues: +15% of which +10% like-for-like

21/01 16:50 Least - MND reports 2014/2015 9-month revenues of EUR 45.7 million

20/10 18:00 Least - H1 2011/12 turnover: EUR 50.0m - Annual objectives confirmed

10/10 11:10 Least - Second part of an exclusive interview with Thierry Ehrmann, CEO of Artprice.com (9 October 2011)

10/09 08:05 Least - Finnish Operator, Blue Lake Communications, Offers Higher Speed Broadband and Advanced IPTV Services With Integrated InCoax Networks, Entropic Communications Access Platform

09/09 19:00 Least - HALF-YEAR RESULTS TO 30 JUNE 2011

30/08 07:30 Least - Strong Growth and Operating Leverage Trebles Eurofins' Net Profit in H1 2011

29/08 10:20 Least - W.P. Stewart and Co., Ltd. Reports Second Half and Full Year 2010 Financial Results and Provides Corporate Update

03/08 09:00 Least - OPNET Announces Financial Results for First Quarter of Fiscal 2012

29/07 18:00 Least - GROUPE STERIA SCA - SHARE CAPITAL INCREASE RESERVED FOR EMPLOYEES

28/07 18:50 Least - Organic revenue growth of 5.6% in the second quarter of 2011. 15.5% increase in underlying attributable net income in the first half of 2011

25/07 12:30 Least - Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis